Xenon Pharmaceuticals Inc. Form 8-K August 03, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2016

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

Canada 001-36687 98-0661854 (State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.)

of Incorporation)

200-3650 Gilmore Way

Burnaby, British Columbia V5G 4W8

Canada

(Address of principal executive offices including zip code)

(604) 484-3300
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) "Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) "Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On August 3, 2016, Xenon Pharmaceuticals Inc. (the "Company") announced via press release the Company's financial results for the three and six month periods ended June 30, 2016. A copy of the Company's press release is attached hereto as Exhibit 99.1. The information in this Form 8 K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits (d) Exhibits.

Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:

Exhibit Number Description

99.1 Press Release issued by Xenon Pharmaceuticals Inc. dated August 3, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 3, 2016XENON PHARMACEUTICALS INC.

By: /s/ Ian Mortimer

Ian Mortimer

Chief Financial Officer and Chief Operating Officer

EXHIBIT INDEX

Exhibit Number Description

99.1 Press Release issued by Xenon Pharmaceuticals Inc. dated August 3, 2016.